We also found an obvious difference in the expression of PDCD1 (PD-1), CTLA-4, and HHLA2 between the two groups of patients (Figures 9A,C), indicating a potential role of the risk model in predicting immune responses to immunotherapy in HCC patients. This evidence concerns the gene HHLA2 and hepatocellular carcinoma.